» Authors » Jack C Yalowich

Jack C Yalowich

Explore the profile of Jack C Yalowich including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 51
Citations 547
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Powell J, Mann C, Toth P, Nolan S, Steinert A, Ove C, et al.
ACS Med Chem Lett . 2024 Aug; 15(8):1287-1297. PMID: 39140037
Multidrug-resistant bacterial infections pose an ever-evolving threat to public health. Since the outset of the antibacterial age, bacteria have developed a multitude of diverse resistance mechanisms that suppress the effectiveness...
2.
Wang X, Carvajal-Moreno J, Zhao X, Li J, Hernandez V, Yalowich J, et al.
Mol Pharmacol . 2024 May; 106(1):33-46. PMID: 38719474
DNA topoisomerase II (TOP2; 170 kDa, TOP2/170) is an essential enzyme for proper chromosome dysjunction by producing transient DNA double-stranded breaks and is an important target for DNA damage-stabilizing anticancer...
3.
Carvajal-Moreno J, Wang X, Hernandez V, Mondal M, Zhao X, Yalowich J, et al.
J Pharmacol Exp Ther . 2024 Mar; 389(2):186-196. PMID: 38508753
DNA topoisomerase II (TOP2/180; 180 kDa) is a nuclear enzyme that regulates DNA topology by generation of short-lived DNA double-strand breaks, primarily during transcription. TOP2/180 can be a target for...
4.
Mann C, Carvajal Moreno J, Lu Y, Dellos-Nolan S, Wozniak D, Yalowich J, et al.
Antimicrob Agents Chemother . 2023 Sep; 67(10):e0048223. PMID: 37724886
Antimicrobial resistance has made a sizeable impact on public health and continues to threaten the effectiveness of antibacterial therapies. Novel bacterial topoisomerase inhibitors (NBTIs) are a promising class of antibacterial...
5.
Dauda S, Collins J, Byl J, Lu Y, Yalowich J, Mitton-Fry M, et al.
Int J Mol Sci . 2023 Aug; 24(15). PMID: 37569485
Novel bacterial topoisomerase inhibitors (NBTIs) are an emerging class of antibacterials that target gyrase and topoisomerase IV. A hallmark of NBTIs is their ability to induce gyrase/topoisomerase IV-mediated single-stranded DNA...
6.
Carvajal-Moreno J, Hernandez V, Wang X, Li J, Yalowich J, Elton T
J Pharmacol Exp Ther . 2022 Nov; 384(2):265-276. PMID: 36410793
DNA topoisomerase II (TOP2/170; 170 kDa) and topoisomerase II (TOP2/180; 180 kDa) are targets for a number of anticancer drugs, whose clinical efficacy is attenuated by chemoresistance. Our laboratory selected...
7.
Elton T, Hernandez V, Carvajal-Moreno J, Wang X, Ipinmoroti D, Yalowich J
Cancers (Basel) . 2022 Jul; 14(13). PMID: 35804920
Intronic polyadenylation (IPA) plays a critical role in malignant transformation, development, progression, and cancer chemoresistance by contributing to transcriptome/proteome alterations. DNA topoisomerase IIα (170 kDa, TOP2α/170) is an established clinical...
8.
Lu Y, Mann C, Nolan S, Collins J, Parker E, Papa J, et al.
ACS Med Chem Lett . 2022 Jun; 13(6):955-963. PMID: 35707162
Antibacterial resistance continues its devastation of available therapies. Novel bacterial topoisomerase inhibitors (NBTIs) offer one solution to this critical issue. Two series of amine NBTIs bearing tricyclic DNA-binding moieties as...
9.
Hernandez V, Carvajal-Moreno J, Wang X, Pietrzak M, Yalowich J, Elton T
PLoS One . 2022 May; 17(5):e0265794. PMID: 35617303
DNA Topoisomerase IIα (TOP2α/170) is an enzyme essential for proliferating cells. For rapidly multiplying malignancies, this has made TOP2α/170 an important target for etoposide and other clinically active anticancer drugs....
10.
Aldrich L, Burdette J, de Blanco E, Coss C, Eustaquio A, Fuchs J, et al.
J Nat Prod . 2022 Feb; 85(3):702-719. PMID: 35213158
Research progress from mainly over the last five years is described for a multidisciplinary collaborative program project directed toward the discovery of potential anticancer agents from a broad range of...